Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR

Soochow University

Status

Enrolling

Conditions

Platelet Transfusion Refractoriness

Treatments

Other: Cryopreserved autologous platelet transfusion

Study type

Interventional

Funder types

Other

Identifiers

NCT05761457

20221108091732885

Details and patient eligibility

About

The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR and allo-immunity; Saving platelet resources and reducing blood burden.

Enrollment

25 estimated patients

Sex

All

Ages

15 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with ALL，AML，MDS, CML,CLL that suffered from PTR before, with or without HLA antibodies
The platelet level >150*10E9/L when considering autologous PLT collection
Age less than 70 years
The expected life more than 3 months
Agree to receive autologous platelet cryopreservation and infusion treatment, and sign the informed consent form

Exclusion criteria

Blast cells are found in peripheral blood or bone marrow
Patients with bacteremia or sepsis
Coagulation function abnormality
Patients who have a history of thrombosis and are receiving anticoagulant treatment
Severe bleeding within 2 weeks
Participate in another clinical study within 1 month, and have treatment with potential impact on platelets
Patients with mental disease